Literature DB >> 16225514

Satraplatin in the treatment of hormone-refractory prostate cancer.

Cora N Sternberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16225514     DOI： 10.1111/j.1464-410X.2005.05799.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  8 in total

1.  Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.

Authors:  Ulka N Vaishampayan; Joseph Fontana; Lance K Heilbrun; Daryn Smith; Elisabeth Heath; Brenda Dickow; William D Figg
Journal:  Urol Oncol       Date:  2013-02-21       Impact factor: 3.498

Review 2.  Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

3.  Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Cancer Ther       Date:  2007

4.  New paradigms for advanced prostate cancer.

Authors:  Daniel P Petrylak
Journal:  Rev Urol       Date:  2007

5.  RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

Authors:  Kilian M Gust; Matthias D Hofer; Sven R Perner; Robert Kim; Arul M Chinnaiyan; Sooryanarayana Varambally; Peter Moller; Ludwig Rinnab; Mark A Rubin; Jochen Greiner; Michael Schmitt; Rainer Kuefer; Mark Ringhoffer
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

6.  Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.

Authors:  Filippo Francini; Alessandra Pascucci; Edoardo Francini; Gianluca Bargagli; Raffaele Conca; Antonella Licchetta; Giandomenico Roviello; Ignazio Martellucci; Giorgio Chiriacò; Salvatora Tindara Miano; Giuseppe Marzocca; Antonio Manganelli; Roberto Ponchietti; Vinno Savelli; Roberto Petrioli
Journal:  Prostate Cancer       Date:  2011-08-21

Review 7.  Current perspectives in the treatment of advanced prostate cancer.

Authors:  Victor Valdespino; Panagiotis Tsagozis; Pavel Pisa
Journal:  Med Oncol       Date:  2007       Impact factor: 3.738

8.  Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.

Authors:  Andrew J Armstrong; Daniel J George
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.